NVision
NVision engineers molecular quantum systems for quantum-enhanced metabolic MRI and photonic-interfaced quantum computing.
Founded
2016NVision engineers molecular quantum systems for quantum-enhanced metabolic MRI and photonic-interfaced quantum computing.
NVision sells two named platforms that share an approach of engineering quantum properties into organic molecules rather than adding hardware. POLARIS is a room-temperature hyperpolarizer that amplifies the MRI signal of metabolites such as 13C-enriched pyruvate by more than ten thousand times, and is marketed for preclinical research with development toward an investigational clinical system continuing.
PIQC is a quantum computing architecture built on carbene molecules that act as molecular quantum nodes, combining an optically addressable electron spin with a long-lived nuclear spin memory. The company reports that these molecules can be deposited as thin organic films onto photonic integrated circuits, positioning the design against architectures that require complex hardware to interface qubits with photons.
NVision's near-term market sits with university hospitals, cancer centres and pharmaceutical research groups that run preclinical MRI, a segment where metabolic imaging promises treatment-response readouts in days rather than the months anatomical MRI requires. Partnerships and deployments cited by the company and its Series A announcement include Siemens Healthineers, Memorial Sloan Kettering, and a research site established at Hokkaido University in Japan.
The longer-term opportunity is wider. The company reports selection for Phase 1 of the EuroHPC Joint Undertaking Quantum Grand Challenge and a Horizon Europe-funded project extending POLARIS into South Korea, and its quantum computing platform addresses the drug discovery and diagnostics customers that its imaging division already reaches.
The company's central advantage is that it targets the same molecular engineering method at two markets. Its hyperpolarization work requires the chemistry and spin-physics capability that also underpins its qubit design, so the imaging program funded discovery that the computing program now commercialises. POLARIS is pitched against conventional hyperpolarizers the company describes as slow and difficult to operate in an MRI setting, and it advertises room-temperature operation and a small footprint instead.
Its PIQC architecture claims a native photonic interface built into the molecule rather than added around it, which the company presents as a route to scaling on existing photonic integrated circuit manufacturing. Backing reflects that positioning: Playground Global led its Series A, and Abbott anchored a later round alongside a European Investment Bank venture loan.
The imaging business faces a long regulatory path. The company states that POLARIS is currently available only as a preclinical research system, and that its hyperpolarized imaging agents, including 13C pyruvate, remain investigational and have not received regulatory approval for routine clinical use. Revenue therefore depends on research installations until a clinical system clears approval.
The quantum computing effort is earlier still. Published milestones describe single-molecule demonstrations achieved in 2026 with coherence of around two milliseconds, a long way from the millions-of-qubits systems its roadmap targets. That places the company against better-funded incumbents in superconducting, trapped-ion, neutral-atom and photonic computing.